Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors

BACKGROUND: Eribulin mesylate is a synthetic macrocyclic ketone analogue of Halichondrin B that has demonstrated high antitumor activity in preclinical and clinical settings. This phase I study aimed to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetics...

Descripción completa

Detalles Bibliográficos
Autores principales: Koczywas, M, Frankel, P H, Synold, T W, Lenz, H-J, Mortimer, J E, El-Khoueiry, A B, Gandara, D R, Cristea, M C, Chung, V M, Lim, D, Reckamp, K L, Lau, D H, Doyle, L A, Ruel, C, Carroll, M I, Newman, E M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264453/
https://www.ncbi.nlm.nih.gov/pubmed/25349975
http://dx.doi.org/10.1038/bjc.2014.554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264453/
https://www.ncbi.nlm.nih.gov/pubmed/25349975
http://dx.doi.org/10.1038/bjc.2014.554

Ejemplares similares